Share this article

The US Food and Drug Administration (FDA) has approved Boston Scientific’s Promus Element plus everolimus-eluting platinum chromium coronary stent system.

The Promus Element stent is used to treat patients with coronary artery disease.

The stent system incorporates a low-profile delivery system with a dual-layer balloon and bi-segment inner lumen catheter to provide precise stent delivery across challenging lesions.

The company claims that the everolimus drug and fluorinated copolymer stent coating, which have been studied in multiple randomised clinical trials, showed long-term safety and efficacy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData